dQ&A's latest diabetes research includes two presentations from our team at ATTD 2026, one of the world's leading stages for diabetes advancements.
Our latest Diabetes Drug Insights study follows a group of more than n=3,000 people with type 2 diabetes in the USA from 2018 to 2024.
The latest data in our current survey highlights geographical differences in the comorbidities experienced by people with diabetes along with satisfaction with their glucose control.
In fifteen years of diabetes research, we’ve learned a lot about what drives successful outcomes...
Our research finds that 37% of people with diabetes report poor quality sleep, and about half suffer from restless sleep or have trouble staying asleep.
This study provides real-world evidence on hypoglycemia prevalence, its effects on people, and the implications for HCP & diabetes manufacturers.
dQ&A Presented Three Abstracts at EASD 2023 | dQ&A
New dQ&A data tracks GLP-1 & SGLT2 trends, patient/HCP insights, satisfaction, and market shifts to guide diabetes drug decisions.
We partnered with LMC to connect real-world patient experience insights with validated clinical data for patients across the diabetes spectrum.
